3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
10
INDUSTRY
6
OTHER_GOV
1
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Head and Neck Neoplasms
1
EGFR Positive Non-small Cell Lung Cancer
1
Colorectal Neoplasms
1
Interventions
Irinotecan
11
Oxaliplatin
8
Cetuximab
7
Fluorouracil
6
Leucovorin
5
Bevacizumab
5
Standard of Care
4
S 1 (combination)
4
Capecitabine
4
trifluridine tipiracil drug combination
2
tislelizumab
2
apatinib
2
Propranolol
2
Preoperative Exercise
2
Panitumumab
2
Levoleucovorin
2
Folfox protocol
2
Etodolac
2
Endoscopic Mucosal Resection
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
trebananib
1
regorafenib
1
envafolimab
1
Trifluridine
1
Thalidomide
1
Surveys and Questionnaires
1
Occult Blood
1
Neoadjuvant Therapy
1
Moxibustion
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Colorectal Neoplasms
×
Erlotinib Hydrochloride
×
Clear all
NCT00784667
2010-11-30
Dux
Austin Health
Phase 2
Unknown
50 enrolled